🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06434649
Active, not recruiting Not applicable

Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer

NCT06434649 · tracked via the Priya Life Science China tracker
Sponsor
Ning Xu
Phase
Not applicable
Started
2025-11-01
Last updated
2026-04-13

Condition(s) studied

Surgical Procedure, UnspecifiedProstate Cancer

Investigational drug(s) / intervention(s)

Extrafascial robotic assisted radical prostatectomy via posterior approachExtrafascial robotic assisted radical prostatectomy via anterior approach

Extrafascial robotic assisted radical prostatectomy via posterior approach: Extrafascial robotic assisted radical prostatectomy via posterior approach will be applied in the intermediate or high risk patients.

Extrafascial robotic assisted radical prostatectomy via anterior approach: Extrafascial robotic assisted radical prostatectomy via anterior approach will be applied in the intermediate or high risk patients.

Study summary

This study was designed as a prospective, multicentre, double-blind, randomised controlled clinical trial. It aims to investigate the feasibility and safety of the posterior approach extrafascial technique and the anterior approach extrafascial technique in robot-assisted radical prostatectomy (RARP) for intermediate- and high-risk prostate cancer patients, to compare the oncological prognosis, functional prognosis, and safety of the two techniques in intermediate- and high-risk prostate cancer patients, and to provide evidence-based medical evidence for the choice of surgical treatment modality for intermediate- and high-risk prostate cancer patients.

Eligibility

Sex
MALE
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. intermediate- and high-risk prostate cancer patients assessed by comprehensive clinical evaluation; 2. prostate volume \<80 ml; 3. life expectancy of patients \>10 years; 4. patients sign the "informed consent"; 5. Routine preoperative examination has been improved (chest CT, electrocardiogram, and color Doppler echocardiography), and there is no serious basic disease. After clinical evaluation, it can tolerance robot-assisted radical prostatectomy (RARP). Exclusion Criteria: 1. life expectancy \<10 years; 2. comorbidities with other malignancies; 3. uncorrected coagulation dysfunctions; 4. patients with severe underlying diseases such as severe pulmonary insufficiency who could not tolerate the surgery; 5. patients or family members who did not accept radical prostatectomy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
first hospital affiliated of Fujian medical university Fuzhou Fujian

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06434649 on ClinicalTrials.gov ↗ ← All trials in China